Activation of alternate SEMA3C‐driven RTKs may confer escape mechanisms for acquired resistance to RTK inhibitors such as ErbB2 amplification in breast cancer and MET amplification in colon and lung cancer. This evidence concerns the gene ERBB2 and lung carcinoma.